Skip to main content
. 2015 Mar 10;6(10):8144–8154. doi: 10.18632/oncotarget.3519

Table 2. Survival according to MAPKBP1 expression in all patients and European Leukemia Net Genetic Groups.

Outcome All patients, n=157 ELN Favorable group Intermediate-I
MAPKBP1high, n=78 MAPKBP1low, n=79 P MAPKBP1high, n=19 MAPKBP1low, n=40 P MAPKBP1high, n=68 MAPKBP1low, n=54 P
OS
 Median OS, m 10.46
(0.07-198.7)
43.47
(0.13-214.5)
0.00
7
20.01
(1.05-163.10)
52.28
(0.3-214.5)
0.2
7
8.49
(0.07-198.7)
39.54
(0.13-190.3)
0.04
 Estimated OS at 3 y. % (95% CI) 0.29
(0.21-0.42)
0.58
(0.48-0.70)
0.01 0.42 (0.25-0.71) 0.63
(0.49-0.80)
0.1
9
0.264
(0.18-0.4)
0.56
(0.44-0.71)
0.04
EFS
 Median EFS, m 7.64
(0.03-198.7)
28.12
(0.03-214.5)
0.00
4
11.93
(0.03-131.9)
40.48
(0.03-214.5)
0.2
1
6.83
(0.03-198.7)
24.94
(0.03-190.3)
0.00
9
 Estimated EFS at 3 y. % (95% CI) 0.23
(0.15-0.35)
0.46
(0.36-0.58)
0.00
2
0.37 (0.20-0.66) 0.55
(0.42-0.73)
0.0
6
0.19
(0.12-0.31)
0.41
(0.29-0.56)
0.00
3

OS, overall survival; CI, confidence interval; EFS, event-free survival.